Loading...
Semler Scientific reported a 30% increase in revenue, reaching $18.2 million, and a 48% increase in net income, amounting to $5.0 million for Q1 2023. The company's cash, cash equivalents, and short-term investments totaled $43.0 million.
Revenue increased by 30% to $18.2 million compared to Q1 2022.
Net income increased by 48% to $5.0 million compared to Q1 2022.
Cash, cash equivalents, and short-term investments totaled $43.0 million.
The company is focused on developing its business in heart dysfunction and diabetes.
Semler Scientific is focused on developing its business in two new disease areas, heart dysfunction and diabetes.